HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis wraps up Alcon majority stake

This article was originally published in The Tan Sheet

Executive Summary

Novartis acquires Nestle's 52 percent stake in Alcon for $28.3 billion, giving Novartis a total of 77 percent ownership in the eye care firm. With the Nestle deal completed Aug. 26, Novartis continues its quest for the remaining 23 percent of Alcon held by independent stockholders, who have rejected Novartis' proposed purchase price as inadequate (1"The Tan Sheet" Aug. 23, 2010). "We are ready to defend the rights of Alcon and its minority shareholders if Novartis refuses to negotiate a fair deal," said Thomas Plaskett, chairman of Alcon's independent director committee

You may also be interested in...

Sales & Earnings In Brief

GSK consumer sales grow despite overall dip: Factors including U.S. health care reform and austerity measures in Europe slow GlaxoSmithKline's third-quarter sales, even as consumer health sales grew 4 percent to £1.26 billion ($1.98 billion). The consumer product growth came in markets outside the U.S. and Europe, which were down 4 percent and 2 percent, respectively, the U.K. firm said Oct. 21. Global OTC drug sales were flat, up 1 percent, to $946.7 million. CEO Andrew Witty noted success in the smoking cessation category, particularly the launch of Nicorette Mini-Lozenges. Oral care sales grew 4 percent to $630 million worldwide, with Sensodyne toothpaste reaching double-digit growth for the sixth consecutive quarter. Witty added the firm has "a lot of interesting stuff coming on the Sensodyne portfolio." Glaxo said withdrawal of the Rx weight-loss drug Avandia from the European market and restrictions on its sales in the U.S., following safety reviews, and generic competition to the Rx herpes treatment Valtrex also influenced its overall performance as sales fell 2 percent to $10.7 billion. The firm's third-quarter earnings, excluding restructuring costs, fell 3.5 percent to $2 billion

Novartis Weighs Sweetening Buyout Offer As Alcon Shareholders Fight Back

Independent Alcon shareholders have held out for months for a per-share buyout offer that's closer to the price Novartis is paying for the majority of the company. If Novartis wants to avoid an extended legal battle, it may accede to their demands

QUOTED. 25 February 2020. David Maman.

Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.   





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts